Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on February 8, 2024. The report addresses amendments to retention and separation agreements for two senior executives originally disclosed in May 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes
The primary material change involves the extension of separation dates for two officers:
- Michel Dahan (Chief Operating Officer): Separation date extended from March 22, 2024, to June 28, 2024.
- Nicole R. Hadas (Senior Vice President, Chief Legal Officer, and Secretary): Separation date extended from March 29, 2024, to June 14, 2024.
These extensions were agreed upon on February 8, 2024, under the "Dahan February 2024 Amendment" and "Hadas February 2024 Amendment."
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or general risk factors. The only contingency noted is that the original separation agreements allowed for an extension to September 2024 in the event of certain specified events, though the current amendments set specific dates in June 2024.
Investor Verification Checklist
- Verify the specific terms of the "Dahan February 2024 Amendment" and "Hadas February 2024 Amendment" when filed as exhibits to the Annual Report on Form 10-K for the year ended December 31, 2023.
- Confirm the impact of these extended departures on the company's operational continuity and legal strategy.
- Review the upcoming Form 10-K for any financial implications related to these executive separations.